Case number 2019-1172
Boehringer Ingelheim v. Mylan Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | BOEHRINGER INGELHEIM v. MYLAN PHARMACEUTICALS INC. [OPINION] [nonprecedential] (0) |
| Apr 22, 2020 | 84 | Mandate issued to the United States District Court for the District of New Jersey. Service as of this date by the Clerk of Court. [689170] [JAB] [Entered: 04/22/2020 01:25 PM] (2) |
| Mar 16, 2020 | 83 | JUDGMENT. REVERSED-IN-PART, AFFIRMED-IN-PART, AND REMANDED. Terminated on the merits after oral argument. COSTS: Each side bears its own costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [678903] [JAB] [Entered: 03/16/2020 09:32 AM] (2) |
| Mar 16, 2020 | 82 | OPINION filed for the court by Dyk, Circuit Judge; Moore, Circuit Judge and Hughes, Circuit Judge. Nonprecedential Opinion. [678902] [JAB] [Entered: 03/16/2020 09:31 AM] (11) |
| Feb 5, 2020 | 81 | Submitted after ORAL ARGUMENT by Leora Ben-Ami, Esq. for Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. and Deepro Mukerjee for Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited, Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. Panel: Judge: Dyk , Judge: Moore , Judge: Hughes. [668557] [JCP] [Entered: 02/05/2020 10:38 AM] (0) |
| Jan 15, 2020 | 80 | Response to notice of oral argument from the Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. [663427] [19-1172] [Leora Ben-Ami] [Entered: 01/15/2020 03:16 PM] (3) |
| Jan 15, 2020 | 79 | Response to notice of oral argument from the Appellees Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited Aurobindo Pharma Limited, and Aurobindo Pharma USA, Inc. [663374] [19-1172]--[Edited 01/16/2020 by JAB to correct filers] [Deepro Mukerjee] [Entered: 01/15/2020 02:01 PM] (3) |
| Dec 17, 2019 | 78 | NOTICE OF ORAL ARGUMENT. Panel: 2002H. Case scheduled February 5, 2020 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 402. Response to Notice of Oral Argument due: 01/15/2020. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [657307] [MJL] [Entered: 12/17/2019 05:42 PM] (2) |
| Oct 29, 2019 | 77 | The following conflict dates submitted by Attorney Leora Ben-Ami for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. have been accepted by the court: 04/06/2020, 04/07/2020. [645332] [JAB] [Entered: 10/29/2019 07:47 AM] (0) |
| Oct 29, 2019 | 76 | The following conflict dates submitted by Attorney Deepro Mukerjee for Appellees Mylan Pharmaceuticals Inc., Mylan Inc. and Mylan Laboratories Limited have been accepted by the court: 01/06/2020, 01/07/2020, 01/08/2020, 01/09/2020, 01/10/2020. [645331] [JAB] [Entered: 10/29/2019 07:46 AM] (0) |
| Oct 28, 2019 | 75 | Notice from Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. regarding conflicts with oral argument. Service: 10/28/2019 by email. [645324] [19-1172] [Leora Ben-Ami] [Entered: 10/28/2019 11:09 PM] (2) |
| Oct 28, 2019 | 74 | Notice from Appellees Mylan Pharmaceuticals Inc., Mylan Inc. and Mylan Laboratories Limited regarding conflicts with oral argument. Service: 10/28/2019 by email. [645258] [19-1172] [Deepro Mukerjee] [Entered: 10/28/2019 04:16 PM] (2) |
| Oct 28, 2019 | 73 | 6 paper copies of the Corrected Confidential Appendix Brief (Vol. I - XI) [64] received from Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. and Appellees Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc.. [645076] [CJF] [Entered: 10/28/2019 11:14 AM] (0) |
| Oct 25, 2019 | 72 | 6 paper copies of the Reply Brief [50] received from Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. [644971] [CJF] [Entered: 10/28/2019 07:20 AM] (0) |
| Oct 25, 2019 | 71 | 6 paper copies of the Corrected Confidential Opening Response Brief [46] received from Appellees Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc.. [644970] [CJF] [Entered: 10/28/2019 07:20 AM] (0) |
| Oct 25, 2019 | 70 | 6 paper copies of the Corrected Confidential Opening Brief [57] received from Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. [644969] [CJF] [Entered: 10/28/2019 07:18 AM] (0) |
| Oct 24, 2019 | 69 | The following conflict dates submitted by Attorney Leora Ben-Ami for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. have been accepted by the court: 04/08/2020, 04/09/2020, 04/10/2020. [644352] [JAB] [Entered: 10/24/2019 10:06 AM] (0) |
| Oct 23, 2019 | 68 | Notice from Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. regarding conflicts with oral argument. Service: 10/23/2019 by email. [644310] [19-1172] [Leora Ben-Ami] [Entered: 10/23/2019 10:52 PM] (2) |
| Oct 21, 2019 | 67 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [643451] [TAM] [Entered: 10/21/2019 01:33 PM] (1) |
| Oct 21, 2019 | 66 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(1). [643450] [TAM] [Entered: 10/21/2019 01:32 PM] (0) |
| Oct 3, 2019 | 65 | RESPONSE of Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. to the supplemental authority [62] filed by Appellees Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited, Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc.. Service: 10/03/2019 by email. [640076] [19-1172] [Leora Ben-Ami] [Entered: 10/03/2019 02:40 PM] (3) |
| Sep 12, 2019 | 64 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL APPENDIX FILED for Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. and Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc.. Number of Pages: 7034. Service: 09/12/2019 by email. [635192]--[Edited 10/21/2019 by TAM - compliance review complete] [Leora Ben-Ami] [Entered: 09/12/2019 05:27 PM] (0) |
| Sep 12, 2019 | 63 | MODIFIED ENTRY: CORRECTED APPENDIX FILED for Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. and Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc.. Number of Pages: 1556. Service: 09/12/2019 by email. [635189] --[Edited 10/21/2019 by TAM - compliance review complete] [Leora Ben-Ami] [Entered: 09/12/2019 05:12 PM] (1556) |
| Sep 10, 2019 | 62 | MODIFIED ENTRY: Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellees Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc.. Service: 09/10/2019 by email. [634457]--[Edited 09/12/2019 by JCA - Reason: to correct filing event] [Deepro Mukerjee] [Entered: 09/10/2019 04:17 PM] (37) |
| Sep 5, 2019 | 61 | NOTICE OF NON-COMPLIANCE: The submissions of Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. and Appellees Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc., Confidential and Non-Confidential Appendix [59], [60], are not in compliance with the rules of this court (see attached). Compliant documents due on 09/12/2019. Service as of this date by the Clerk of Court. [633400] [TAM] [Entered: 09/05/2019 01:45 PM] (2) |
| Aug 21, 2019 | 60 | FILED from Appellees Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Title: APPENDIX. Service: 08/21/2019 by email. [630068] [19-1172] This document is non-compliant. See Doc No.[61] [Leora Ben-Ami] [Entered: 08/21/2019 05:10 PM] (2442) |
| Aug 21, 2019 | 59 | FILED from Appellees Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Title: CONFIDENTIAL APPENDIX. Service: 08/21/2019 by email. [630058] [19-1172] This document is non-compliant. See Doc No.[61] [Leora Ben-Ami] [Entered: 08/21/2019 04:56 PM] (0) |
| Aug 16, 2019 | 58 | MODIFIED ENTRY: CORRECTED OPENING BRIEF FILED for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Number of Pages: 72. Service: 08/16/2019 by email. [629069]--[Edited 08/22/2019 by TAM - compliance review complete] [Leora Ben-Ami] [Entered: 08/16/2019 04:28 PM] (253) |
| Aug 16, 2019 | 57 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL OPENING BRIEF FILED for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. Number of Pages: 72. Service: 08/16/2019 by US mail, email. [629066]--[Edited 08/22/2019 by TAM - compliance review complete] [Leora Ben-Ami] [Entered: 08/16/2019 04:23 PM] (0) |
| Aug 16, 2019 | 56 | Notice of Correction to Doc No. [33], [33], [32], [32] for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Service: 08/16/2019 by email. [629063] [19-1172] [Leora Ben-Ami] [Entered: 08/16/2019 04:19 PM] (5) |
| Aug 15, 2019 | 55 | **TEXT ONLY** ORDER granting motion to extend time to file appendix [52] filed by Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. The appendix is due 08/21/2019. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [628371] [TAM] [Entered: 08/15/2019 09:41 AM] (0) |
| Aug 14, 2019 | 54 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellees Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Service: 08/14/2019 by email. [628304] [19-1172] [Leora Ben-Ami] [Entered: 08/14/2019 05:53 PM] (5) |
| Aug 14, 2019 | 53 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Service: 08/14/2019 by email. [628302] [19-1172] [Leora Ben-Ami] [Entered: 08/14/2019 05:51 PM] (4) |
| Aug 14, 2019 | 52 | MOTION of Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. to extend the time to 08/21/2019 to file the appendix. [Consent: unopposed]. Service: 08/14/2019 by email. [628301] [19-1172] [Leora Ben-Ami] [Entered: 08/14/2019 05:48 PM] (11) |
| Aug 8, 2019 | 51 | Amended Entry of appearance for Paige S. Stradley as of counsel for Appellees Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.. Service: 08/08/2019 by email. [627091] [19-1172] [Paige Stradley] [Entered: 08/08/2019 04:44 PM] (2) |
| Aug 7, 2019 | 50 | MODIFIED ENTRY: REPLY BRIEF FILED for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Number of Pages: 34. Service: 08/07/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [626867] --[Edited 08/22/2019 by TAM - compliance review complete] [Leora Ben-Ami] [Entered: 08/07/2019 09:53 PM] (43) |
| Aug 7, 2019 | 49 | Amended Entry of appearance for Liza M. Walsh as of counsel for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Service: 08/07/2019 by email. [626800] [19-1172] [Liza Walsh] [Entered: 08/07/2019 04:54 PM] (3) |
| Aug 7, 2019 | 48 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a) and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [CLERKâS NOTE: Attorney Liza M. Walsh should promptly file an Entry of Appearance with updated contact information.] [626751] [TAM] [Entered: 08/07/2019 04:07 PM] (0) |
| Aug 7, 2019 | 47 | Letter from Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. Re: Notice of Change of Address. Service: 08/07/2019 by email. [626741] [19-1172] [Liza Walsh] [Entered: 08/07/2019 03:55 PM] (2) |
| Jul 1, 2019 | 46 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL RESPONSE BRIEF FILED for Appellees Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc. Number of Pages: 56. Service: 07/01/2019 by email, US mail. [618352]--[Edited 07/10/2019 by TAM - compliance review complete] [Deepro Mukerjee] [Entered: 07/01/2019 04:45 PM] (0) |
| Jul 1, 2019 | 45 | MODIFIED ENTRY: CORRECTED RESPONSE BRIEF FILED for Appellees Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc. Number of Pages: 56. Service: 07/01/2019 by email. [618351] --[Edited 07/10/2019 by TAM - compliance review complete] [Deepro Mukerjee] [Entered: 07/01/2019 04:43 PM] (73) |
| Jul 1, 2019 | 44 | Notice of Correction to the Brief Doc No. [39], confidential Brief Doc No. [40] for Appellees Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited, Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.. Service: 07/01/2019 by email. [618348] [19-1172] [Deepro Mukerjee] [Entered: 07/01/2019 04:38 PM] (5) |
| Jun 24, 2019 | 43 | NOTICE OF NON-COMPLIANCE: The submissions of Appellees Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc., Confidential and Non-Confidential Response Brief [39], [40], are not in compliance with the rules of this court (see attached). Compliant documents due on 07/01/2019. Service as of this date by the Clerk of Court. [616306] [TAM] [Entered: 06/24/2019 10:56 AM] (2) |
| Jun 19, 2019 | 42 | **TEXT ONLY** ORDER granting motion to extend time to file Appellants' reply brief [41] filed by Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. Brief is due 08/07/2019. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [615554] [TAM] [Entered: 06/19/2019 02:00 PM] (0) |
| Jun 19, 2019 | 41 | MOTION of Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. to extend the time to 08/07/2019 to file the Appellants' Reply Brief. [Consent: unopposed]. Service: 06/19/2019 by email. [615509] [19-1172] [Leora Ben-Ami] [Entered: 06/19/2019 12:30 PM] (7) |
| Jun 17, 2019 | 40 | FILED from Appellees Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited, Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.. Title: CONFIDENTIAL RESPONSE BRIEF. Service: 06/17/2019 by email. [614883] [19-1172] This document is non-compliant. See Doc No.[43] [Deepro Mukerjee] [Entered: 06/17/2019 06:14 PM] (0) |
| Jun 17, 2019 | 39 | FILED from Appellees Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited, Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.. Title: RESPONSE BRIEF. Service: 06/17/2019 by email. [614882] [19-1172] This document is non-compliant. See Doc No.[43] [Deepro Mukerjee] [Entered: 06/17/2019 06:10 PM] (72) |
| May 22, 2019 | 38 | Amended Entry of appearance for Wendy M. Ward as of counsel for Appellees Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.. Service: 05/22/2019 by email. [609075] [19-1172] [Jeffrey Ward] [Entered: 05/22/2019 02:42 PM] (2) |
| May 22, 2019 | 37 | Amended Entry of appearance for Jeffrey S. Ward as principal counsel for Appellees Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.. Service: 05/22/2019 by email. [609073] [19-1172] [Jeffrey Ward] [Entered: 05/22/2019 02:37 PM] (2) |
| Mar 28, 2019 | 36 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: motion to extend time to file brief Docket No. [34], ERROR: The motion did not include a completed certificate of interest. CORRECTION: For future filings requiring an attached certificate of interest, please ensure that all questions have been answered. [596042] [TAM] [Entered: 03/28/2019 08:29 AM] (0) |
| Mar 28, 2019 | 35 | **TEXT ONLY** ORDER granting motion to extend time to file Appellee's brief [34] filed by Appellees Mylan Pharmaceuticals Inc., Mylan Inc. and Mylan Laboratories Limited. Brief due 06/17/2019. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [596039] [TAM] [Entered: 03/28/2019 08:24 AM] (0) |
| Mar 27, 2019 | 34 | MOTION of Appellees Mylan Pharmaceuticals Inc., Mylan Inc. and Mylan Laboratories Limited to extend the time to 06/17/2019 to file the Appellees' Opposition Brief. [Consent: unopposed]. Service: 03/27/2019 by email. [596011] [19-1172] [Deepro Mukerjee] [Entered: 03/27/2019 05:08 PM] (9) |
| Mar 8, 2019 | 33 | MODIFIED ENTRY: BRIEF FILED for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. Number of Pages: 72. Service: 03/08/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [591648] --[Edited 03/14/2019 by MMA - Reason: compliance review complete] This brief has been corrected. See Doc No.[58] [Leora Ben-Ami] [Entered: 03/08/2019 05:37 PM] (253) |
| Mar 8, 2019 | 32 | MODIFIED ENTRY: CONFIDENTIAL BRIEF FILED for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. Number of Pages: 72. Service: 03/08/2019 by US mail, email. [591647]--[Edited 03/14/2019 by MMA - Reason: compliance review complete] This brief has been corrected. See Doc No.[57] [Leora Ben-Ami] [Entered: 03/08/2019 05:31 PM] (0) |
| Dec 4, 2018 | 31 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: motion to extend time to file brief Docket No. [29], ERROR: Document's caption does not follow official caption provided by the clerk. CORRECTION: For future filings requiring the official caption, please ensure the caption is correct. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [569615] [TAM] [Entered: 12/04/2018 02:39 PM] (0) |
| Dec 4, 2018 | 30 | ORDER granting motion to extend time to file brief [29] filed by Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. No further extensions should be anticipated. Brief is due 03/08/2019. Service as of this date by the Clerk of Court. [569609] [TAM] [Entered: 12/04/2018 02:30 PM] (2) |
| Nov 30, 2018 | 29 | MOTION of Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. to extend the time to 03/08/2019 to file the Appellants' Opening Appeal Brief. [Consent: unopposed]. Service: 11/30/2018 by email. [569067] [19-1172] [Leora Ben-Ami] [Entered: 11/30/2018 06:43 PM] (8) |
| Nov 28, 2018 | 28 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:party notice Docket No. [27], ERROR: Document's caption does not follow official caption provided by the clerk. CORRECTION: For future filings requiring the official caption, please ensure the caption is correct. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [568056] [TAM] [Entered: 11/28/2018 09:01 AM] (0) |
| Nov 26, 2018 | 27 | Notice of intent to file corresponding briefs on CD-ROM for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Service: 11/26/2018 by email. [567670] [19-1172] [Leora Ben-Ami] [Entered: 11/26/2018 10:19 PM] (3) |
| Nov 26, 2018 | 26 | Certificate of Interest for the Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Service: 11/26/2018 by email. [567669] [19-1172] [Leora Ben-Ami] [Entered: 11/26/2018 09:41 PM] (3) |
| Nov 26, 2018 | 25 | Docketing Statement for the Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Service: 11/26/2018 by email. [567668] [19-1172] [Leora Ben-Ami] [Entered: 11/26/2018 09:35 PM] (3) |
| Nov 26, 2018 | 24 | Entry of appearance for Jeanna Wacker as of counsel for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. and Boehringer Ingelheim Pharma GmbH & Co. KG. Service: 11/26/2018 by email. [567667] [19-1172] [Leora Ben-Ami] [Entered: 11/26/2018 09:28 PM] (3) |
| Nov 26, 2018 | 23 | Entry of appearance for Lance A. Soderstrom as of counsel for Appellees Mylan Pharmaceuticals Inc., Mylan Inc. and Mylan Laboratories Limited. Service: 11/26/2018 by email. [567549] [19-1172] [Lance Soderstrom] [Entered: 11/26/2018 03:56 PM] (3) |
| Nov 26, 2018 | 22 | Certificate of Interest for the Appellees Mylan Pharmaceuticals Inc., Mylan Inc. and Mylan Laboratories Limited. Service: 11/26/2018 by email. [567541] [19-1172] [Deepro Mukerjee] [Entered: 11/26/2018 03:48 PM] (3) |
| Nov 26, 2018 | 21 | Entry of appearance for Rajesh R. Srinivasan as of counsel for Appellees Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc.. Service: 11/26/2018 by email. [567540] [19-1172] [Rajesh Srinivasan] [Entered: 11/26/2018 03:48 PM] (3) |
| Nov 26, 2018 | 20 | Docketing Statement for the Appellees Mylan Pharmaceuticals Inc., Mylan Inc. and Mylan Laboratories Limited. Service: 11/26/2018 by email. [567538] [19-1172] [Deepro Mukerjee] [Entered: 11/26/2018 03:45 PM] (3) |
| Nov 26, 2018 | 19 | Entry of appearance for Joseph M. Janusz as of counsel for Appellees Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc.. Service: 11/26/2018 by email. [567537] [19-1172] [Joseph Janusz] [Entered: 11/26/2018 03:43 PM] (3) |
| Nov 26, 2018 | 18 | Entry of appearance for Deepro R. Mukerjee as principal counsel for Appellees Mylan Pharmaceuticals Inc., Mylan Inc. and Mylan Laboratories Limited. Service: 11/26/2018 by email. [567535] [19-1172] [Deepro Mukerjee] [Entered: 11/26/2018 03:42 PM] (3) |
| Nov 26, 2018 | 17 | Entry of appearance for Eric T. Werlinger as of counsel for Appellees Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc.. Service: 11/26/2018 by email. [567532] [19-1172] [Eric Werlinger] [Entered: 11/26/2018 03:36 PM] (3) |
| Nov 26, 2018 | 16 | Entry of appearance for Howard R. Rubin as of counsel for Appellees Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan Inc.. Service: 11/26/2018 by email. [567528] [19-1172] [Howard Rubin] [Entered: 11/26/2018 03:32 PM] (3) |
| Nov 26, 2018 | 15 | Entry of appearance for Thomas J. Parker as of counsel for Appellees Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc.. Service: 11/26/2018 by email. [567521] [19-1172] [Thomas Parker] [Entered: 11/26/2018 03:22 PM] (2) |
| Nov 26, 2018 | 14 | Entry of appearance for Christopher L. McArdle as of counsel for Appellees Mylan Inc., Mylan Laboratories Limited and Mylan Pharmaceuticals Inc.. Service: 11/26/2018 by email. [567518] [19-1172] [Christopher McArdle] [Entered: 11/26/2018 03:15 PM] (2) |
| Nov 26, 2018 | 13 | Entry of appearance for LIZA M. WALSH as of counsel for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Service: 11/26/2018 by email. [567481] [19-1172] [Liza Walsh] [Entered: 11/26/2018 02:12 PM] (3) |
| Nov 26, 2018 | 12 | Certificate of Interest for the Appellees Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.. Service: 11/26/2018 by email. [567454] [19-1172] [Jeffrey Ward] [Entered: 11/26/2018 01:15 PM] (3) |
| Nov 26, 2018 | 11 | Docketing Statement for the Appellees Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.. Service: 11/26/2018 by email. [567451] [19-1172] [Jeffrey Ward] [Entered: 11/26/2018 01:14 PM] (4) |
| Nov 26, 2018 | 10 | Entry of appearance for Paige S. Stradley as of counsel for Appellees Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.. Service: 11/26/2018 by email. [567446] [19-1172] [Jeffrey Ward] [Entered: 11/26/2018 01:12 PM] (2) |
| Nov 26, 2018 | 9 | Entry of appearance for Wendy M. Ward as of counsel for Appellees Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.. Service: 11/26/2018 by email. [567441] [19-1172] [Jeffrey Ward] [Entered: 11/26/2018 01:10 PM] (2) |
| Nov 26, 2018 | 8 | Entry of appearance for Jeffrey S. Ward as principal counsel for Appellees Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.. Service: 11/26/2018 by email. [567438] [19-1172] [Jeffrey Ward] [Entered: 11/26/2018 01:07 PM] (2) |
| Nov 20, 2018 | 7 | Corrected Entry of appearance for Leora Ben-Ami as principal counsel for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Service: 11/20/2018 by email. [566728] [19-1172] [Mira Mulvaney] [Entered: 11/20/2018 11:54 AM] (3) |
| Nov 20, 2018 | 6 | Corrected Entry of appearance for Mira Mulvaney as of counsel for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Service: 11/20/2018 by email. [566724] [19-1172] [Mira Mulvaney] [Entered: 11/20/2018 11:50 AM] (3) |
| Nov 20, 2018 | 5 | NOTICE OF NON-COMPLIANCE: The submissions of Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc., EOA-Leora Ben-Ami and Mira Mulvaney [3], [2], are not in compliance with the rules of this court (see attached). Compliant documents due on 11/29/2018. Service as of this date by the Clerk of Court.[566650] [TAM] [Entered: 11/20/2018 10:51 AM] (1) |
| Nov 19, 2018 | 4 | Transcript Purchase Order Form for the Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc. indicating that a transcript is already on file. Service: 11/19/2018 by email. [566498] [19-1172] [Mira Mulvaney] [Entered: 11/19/2018 08:00 PM] (2) |
| Nov 19, 2018 | 3 | Entry of appearance for Leora Ben-Ami as principal counsel for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Service: 11/19/2018 by email. [566496] [19-1172] This document is non-compliant. See Doc No. [5] [Mira Mulvaney] [Entered: 11/19/2018 07:24 PM] (2) |
| Nov 19, 2018 | 2 | Entry of appearance for Mira Mulvaney as of counsel for Appellants Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim Pharmaceuticals Inc.. Service: 11/19/2018 by email. [566494] [19-1172] This document is non-compliant. See Doc No. [5] [Mira Mulvaney] [Entered: 11/19/2018 07:18 PM] (2) |
| Nov 8, 2018 | 1 | Appeal docketed. Received: 11/06/2018. [563602]Entry of Appearance due 11/26/2018. Certificate of Interest is due on 11/26/2018. Docketing Statement due 11/26/2018. Appellant's brief is due 01/07/2019. [TAM] [Entered: 11/08/2018 02:26 PM] (222) |
